Gene therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) - Global Opportunity Analysis and Industry Forecast, 2017-2023

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Top winning strategies, by year, 2015-2017*
3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
3.2.2.3. Top winning strategies, by company, 2015-2017*

3.3. Top player positioning, 2016
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High investment for R&D activities pertaining to gene therapy
3.5.1.2. Increase in prevalence of cancer
3.5.1.3. Growth in awareness regarding gene therapy

3.5.2. Restraints

3.5.2.1. High cost associated with gene therapies
3.5.2.2. Unwanted immune responses

3.5.3. Opportunity

3.5.3.1. Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Viral vectors

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market Analysis by country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-associated virus
4.2.9. Herpes simplex virus
4.2.10. Poxvirus
4.2.11. Vaccinia virus
4.2.12. Others

4.3. Nonviral techniques

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market Analysis by country
4.3.5. Naked plasmid vector
4.3.6. Gene gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Antigen

5.2.1. Market size and forecast
5.2.2. Market size and forecast by country

5.3. Cytokine

5.3.1. Market size and forecast
5.3.2. Market Analysis, by country

5.4. Tumor suppressor

5.4.1. Market size and forecast
5.4.2. Market Analysis, by country

5.5. Suicide

5.5.1. Market size and forecast
5.5.2. Market Analysis, by country

5.6. Deficiency

5.6.1. Market size and forecast
5.6.2. Market Analysis, by country

5.7. Growth factors

5.7.1. Market size and forecast
5.7.2. Market Analysis, by country

5.8. Receptors

5.8.1. Market size and forecast
5.8.2. Market Analysis, by country

5.9. Others

5.9.1. Market size and forecast
5.9.2. Market Analysis, by country

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Oncological disorders

6.2.1. Market size and forecast
6.2.2. Market Analysis, by country

6.3. Rare diseases

6.3.1. Market size and forecast
6.3.2. Market Analysis, by country

6.4. Cardiovascular diseases

6.4.1. Market size and forecast
6.4.2. Market Analysis, by country

6.5. Neurological disorders

6.5.1. Market size and forecast
6.5.2. Market Analysis, by country

6.6. Infectious diseases

6.6.1. Market size and forecast
6.6.2. Market Analysis, by country

6.7. Other diseases

6.7.1. Market size and forecast
6.7.2. Market Analysis, by country

CHAPTER 7: GENE THERAPY MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by country
7.2.4. Market size and forecast, by vector type
7.2.5. Market size and forecast, by gene type
7.2.6. Market size and forecast, by application

7.2.6.1. U.S. market size and forecast, by vector type
7.2.6.2. U.S. market size and forecast, by gene type
7.2.6.3. U.S. market size and forecast, by application
7.2.6.4. Canada market size and forecast, by vector type
7.2.6.5. Canada market size and forecast, by gene type
7.2.6.6. Canada market size and forecast, by application
7.2.6.7. Mexico market size and forecast, by vector type
7.2.6.8. Mexico market size and forecast, by gene type
7.2.6.9. Mexico market size and forecast, by application

7.3. Europe

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by country
7.3.4. Market size and forecast, by vector type
7.3.5. Market size and forecast, by gene type
7.3.6. Market size and forecast, by application

7.3.6.1. Germany market size and forecast, by vector type
7.3.6.2. Germany market size and forecast, by gene type
7.3.6.3. Germany market size and forecast, by application
7.3.6.4. France market size and forecast, by vector type
7.3.6.5. France market size and forecast, by gene type
7.3.6.6. France market size and forecast, by application
7.3.6.7. UK market size and forecast, by vector type
7.3.6.8. UK market size and forecast, by gene type
7.3.6.9. UK market size and forecast, by application
7.3.6.10. Italy market size and forecast, by vector type
7.3.6.11. Italy market size and forecast, by gene type
7.3.6.12. Italy market size and forecast, by application
7.3.6.13. Spain market size and forecast, by vector type
7.3.6.14. Spain market size and forecast, by gene type
7.3.6.15. Spain market size and forecast, by application
7.3.6.16. Rest of Europe market size and forecast, by vector type
7.3.6.17. Rest of Europe market size and forecast, by gene type
7.3.6.18. Rest of Europe market size and forecast, by application

7.4. Asia-Pacific

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by country
7.4.4. Market size and forecast, by vector type
7.4.5. Market size and forecast, by gene type
7.4.6. Market size and forecast, by application

7.4.6.1. Japan market size and forecast, by vector type
7.4.6.2. Japan market size and forecast, by gene type
7.4.6.3. Japan market size and forecast, by application
7.4.6.4. China market size and forecast, by vector type
7.4.6.5. China market size and forecast, by gene type
7.4.6.6. China market size and forecast, by application
7.4.6.7. India market size and forecast, by vector type
7.4.6.8. India market size and forecast, by gene type
7.4.6.9. India market size and forecast, by application
7.4.6.10. South Korea market size and forecast, by vector type
7.4.6.11. South Korea market size and forecast, by gene type
7.4.6.12. South Korea market size and forecast, by application
7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by country
7.5.4. Market size and forecast, by vector type
7.5.5. Market size and forecast, by gene type
7.5.6. Market size and forecast, by application

7.5.6.1. Brazil market size and forecast, by vector type
7.5.6.2. Brazil market size and forecast, by gene type
7.5.6.3. Brazil market size and forecast, by application
7.5.6.4. South Africa market size and forecast, by vector type
7.5.6.5. South Africa market size and forecast, by gene type
7.5.6.6. South Africa market size and forecast, by application
7.5.6.7. Rest of LAMEA market size and forecast, by vector type
7.5.6.8. Rest of LAMEA market size and forecast, by gene type
7.5.6.9. Rest of LAMEA market size and forecast, by application

CHAPTER 8: COMPANY PROFILE

8.1. Adaptimmune Therapeutics Plc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Biocancell Ltd.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio

8.3. Bluebird Bio, Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. Celgene Corporation

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. Gilead Sciences, Inc.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Glaxosmithkline Plc

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Merck & Co., Inc.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Oncogenex Pharmaceuticals, Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. Spark Therapeutics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 01. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 02. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 03. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 04. GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 05. GLOBAL GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 06. GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 07. ANTIGEN GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. CYTOKINE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 09. TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. SUICIDE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. DEFICIENCY GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. RECEPTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 28. U.S. GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 29. U.S. GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 31. CANADA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 32. CANADA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 34. MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 35. MEXICO GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. EUROPE GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 38. EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 39. EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 40. GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 41. GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 42. GERMANY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 44. FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 45. FRANCE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. UK GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 47. UK GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 48. UK GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 50. ITALY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 51. ITALY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 53. SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 54. SPAIN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 56. REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 57. REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 60. ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 61. ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 63. JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 64. JAPAN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 66. CHINA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 67. CHINA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 68. INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 69. INDIA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 70. INDIA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 71. SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 72. SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 73. SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 77. LAMEA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 80. LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 81. BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 82. BRAZIL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 83. BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 86. SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 89. REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 90. ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT
TABLE 91. ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT
TABLE 92. ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO
TABLE 93. BIOCANCELL LTD.: COMPANY SNAPSHOT
TABLE 94. BIOCANCELL LTD.: PRODUCT CATEGORY
TABLE 95. BIOCANCELL LTD.: PRODUCT PORTFOLIO
TABLE 96. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 97. BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE 98. CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 99. CELGENE CORPORATION: OPERATING SEGMENTS
TABLE 100. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 101. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 102. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 103. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 104. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 105. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 106. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 107. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 110. NOVARTIS AG : OPERATING DIVISION
TABLE 111. NOVARTIS AG : PRODUCT PORTFOLIO
TABLE 112. ONCOGENEX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 113. ONCOGENEX PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 114. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 115. SPARK THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE 116. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL GENE THERAPY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS: BY GENE TYPE, 2016
FIGURE 03. TOP PLAYER POSITIONING, 2016
FIGURE 04. BARGAINING POWER OF BUYERS
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. THREAT OF NEW ENTRANTS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY MARKET
FIGURE 10. COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2016 & 2023 ($MILLION)
FIGURE 11. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NON-VIRAL VECTORS, 2016 & 2023 (%)
FIGURE 12. COMPARATIVE REGIONAL ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 13. COMPARATIVE REGIONAL ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 14. COMPARATIVE REGIONAL ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 15. COMPARATIVE REGIONAL ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 16. COMPARATIVE REGIONAL ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 17. COMPARATIVE REGIONAL ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 18. COMPARATIVE REGIONAL ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2016 & 2023 (%)
FIGURE 19. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2016 & 2023 (%)
FIGURE 20. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2016 & 2023 (%)
FIGURE 21. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2016 & 2023 (%)
FIGURE 22. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2016 & 2023 (%)
FIGURE 23. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2016 & 2023 (%)
FIGURE 24. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2016 & 2023 (%)
FIGURE 25. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2016 & 2023 (%)
FIGURE 26. ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 27. BLUEBIRD BIO, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 28. CELGENE CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 29. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. CELGENE CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. GILEAD SCIENCES, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 32. GILEAD SCIENCES, INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 33. GLAXOSMITHKLINE PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 35. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 36. MERCK & CO., INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. MERCK & CO., INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. NOVARTIS AG: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. NOVARTIS AG: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. ONCOGENEX PHARMACEUTICALS, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 43. SPARK THERAPEUTICS, INC.: REVENUE, 2014-2016 ($MILLION)

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.